CLINICAL TRIAL AGREEMENT
South Carolina, US

Agreement date: [date]

Sponsor: [full legal name and entity type], of [address] (Sponsor).
Institution: [full legal name and entity type], a South Carolina health care institution at [address] (Institution).
Principal Investigator: [name and credentials] (Investigator).

1. Study and approvals
Institution shall conduct at the Site the adult-subject investigational drug study identified in Schedule 1 (Study) strictly under the final Sponsor protocol, FDA-authorized investigational new drug application, investigator brochure, IRB-approved informed-consent materials and written amendments supplied by Sponsor. The Study excludes minors, prisoners, emergency research without consent, controlled substances and non-study clinical care. Enrollment may begin only after Institution holds written approval from an institutional review board complying with 21 CFR Part 56 and, where applicable, 45 CFR Part 46; Investigator has signed the required FDA investigator statement and financial disclosure; the investigational drug has been lawfully shipped; and Sponsor has given written site activation.

Sponsor shall maintain its regulatory authorization, select and monitor qualified investigators, provide current safety and protocol information, supply the investigational drug without charge, and perform sponsor duties under 21 CFR Part 312. Institution shall maintain the Site's licenses and facilities and ensure that Investigator and Study Staff are qualified and trained. No party transfers a regulatory duty except by an effective written transfer permitted by law.

2. Subjects and Study conduct
Institution and Investigator shall recruit without coercion or unlawful discrimination, apply only approved eligibility criteria, obtain and document legally effective informed consent before any Study procedure, and give each subject the signed consent copy. They shall protect subject rights, safety and welfare; follow the randomization, treatment, testing and visit requirements; make contemporaneous source records; and promptly report protocol deviations. Sponsor may not direct clinical care contrary to Investigator's judgment or the subject's interests. Investigator may deviate without prior approval only to eliminate an immediate hazard, with prompt Sponsor and IRB reporting.

Institution shall not charge a subject or third-party payer for the investigational drug or any item Sponsor pays under the Budget. Routine care may be billed only when lawful, medically necessary, disclosed in the consent and not prohibited by payer terms. Sponsor is the responsible party for ClinicalTrials.gov registration and results reporting unless Schedule 1 lawfully designates another responsible party that accepts the duty in writing.

3. Drug control, safety and reports
Institution shall receive, secure, dispense and account for the investigational drug only through authorized Study personnel; use it only for enrolled subjects; keep temperature, receipt, dispensing, return and destruction records; and return or destroy unused supply only on Sponsor's written instructions consistent with law. Sponsor retains title to unused investigational drug.

Institution and Investigator shall report adverse events, serious adverse events, pregnancies and unanticipated problems within the Protocol and legally required times, providing follow-up information. Sponsor shall promptly communicate new risk information, safety measures, regulatory holds and determinations that may affect willingness to participate. Each party shall make required reports to FDA and the IRB for the responsibilities assigned to it by law. Investigator shall provide progress and final reports and remain available for reasonable safety follow-up.

4. Data, records and privacy
Institution owns and controls original patient medical records and Study source records in its custody. Sponsor owns the completed case-report data, analyses and regulatory submission materials it creates, subject to subject rights and applicable law. Institution shall enter accurate, attributable and timely data, correct supported queries, keep the delegation and consent records, and retain essential Study records until Sponsor gives written confirmation that applicable FDA and other retention periods have ended. It shall not destroy records under legal hold.

Sponsor and monitors may review Study records at the Site during reasonable hours to verify data and compliance, but may access identifiable medical information only as authorized by the subject, IRB waiver or other lawful basis. Institution shall protect physician patient records under South Carolina law and HIPAA. The parties shall use coded identifiers in Sponsor datasets where practicable, limit information to the Study purpose, use appropriate safeguards and report an unauthorized access or disclosure to the other within two calendar days. Sponsor shall not use identifiable information for marketing, employment, insurance underwriting or unrelated research. Each party remains responsible for its own HIPAA role; this Agreement does not by itself create a business-associate relationship.

5. Monitoring, audit and inspection
Sponsor may monitor and audit Study conduct, facilities, drug accountability and records on reasonable notice without materially disrupting care. Institution shall allow FDA and other lawful authorities the access required by law and promptly notify Sponsor of an inspection concerning the Study unless prohibited. Sponsor shall provide material audit findings; Institution shall timely correct supported deficiencies. Sponsor pays its monitoring costs. Institution shall preserve legally protected peer-review material unless disclosure is required by law.

6. Budget and subject injury
Sponsor shall pay Institution the noncontingent amounts in Schedule 2 for completed visits and specified start-up, pharmacy and close-out work after a correct invoice. Payment is not conditioned on favorable results, referrals or purchases. Institution shall not pay enrollment incentives to Study Staff unless disclosed, reasonable and IRB-permitted.

Sponsor shall pay reasonable and necessary medical expenses for diagnosis and treatment of an injury directly caused by the investigational drug or a Protocol-required procedure that the subject would not otherwise have received, except to the extent caused by Institution's or Investigator's failure to follow the Protocol, negligence or willful misconduct, or by the subject's underlying condition. This promise does not require a subject to waive legal rights and shall be described accurately in the consent. Institution shall notify Sponsor promptly and cooperate with documentation. Each party shall maintain insurance in Schedule 1.

7. Inventions, publication and confidentiality
Each party retains technology and materials it owned or developed independently of the Study. Institution assigns to Sponsor an invention conceived and reduced to practice solely through use of the investigational drug or confidential Protocol and directly resulting from Study performance, excluding Institution's general clinical methods and improvements not specific to Sponsor's drug. Inventorship follows United States patent law. Institution shall disclose an assigned invention promptly and execute reasonable documents at Sponsor's expense. Sponsor grants Institution a nonexclusive, noncommercial license to use Study data for patient care, internal education and research after publication, subject to privacy.

Institution may publish Site results after a multi-site primary publication or twelve months after Study completion at all sites, whichever occurs first. It shall give Sponsor a draft at least thirty days before submission. Sponsor may require removal of its confidential information and delay submission up to sixty additional days to file patent applications, but may not suppress or alter accurate results. Authorship follows actual scholarly contribution.

Each party shall protect the other's marked or reasonably understood confidential information, use it only for the Study and disclose it only to persons bound to protect it. This excludes information lawfully public, already known without duty, independently developed or lawfully received from another source. A compelled disclosure requires prompt notice where lawful. Subject safety reporting and lawful publication are not prohibited.

8. Responsibility, term and termination
Sponsor shall defend and indemnify Institution and its personnel against third-party claims to the extent caused by the investigational drug, Sponsor materials or Sponsor breach, except to the extent caused by an indemnified person's negligence, willful misconduct or Protocol violation. Institution shall defend and indemnify Sponsor against third-party claims to the extent caused by Institution's negligence, willful misconduct or material Protocol violation. The party seeking protection shall give prompt notice, reasonable cooperation and control of defense subject to consent for a settlement admitting fault or imposing nonmonetary obligations.

This Agreement begins on the Agreement date and ends after close-out, final data delivery, payment and authorized drug disposition. Either party may terminate on thirty days' notice or immediately for subject-safety risk, withdrawn approval, regulatory hold, material breach not cured within ten days, or insolvency. Institution may stop enrollment whenever Investigator reasonably determines safety requires. On termination Institution shall stop new enrollment, protect subjects, complete required follow-up, account for drug, deliver earned data and preserve records; Sponsor shall pay earned, noncancelable and orderly close-out costs. Privacy, records, publication, intellectual property, accrued payment, indemnity and subject-injury duties survive as applicable.

9. General terms
The parties are independent contractors. Neither may assign this Agreement without written consent, except Sponsor may assign it with the Study and investigational drug to a successor that assumes all duties and has lawful regulatory authority. Notices are effective on actual receipt at Schedule 1 contacts. South Carolina law governs, together with controlling federal law. Nothing waives nonwaivable subject rights or limits FDA, IRB or governmental authority. This Agreement, Schedules and incorporated final Protocol are the entire agreement; a signed amendment is required, but the parties shall implement an urgent safety change when law requires. Counterparts and electronic signatures form one agreement.

SCHEDULE 1 — STUDY DETAILS
Protocol title/number/version/date: [details]. IND number and investigational drug: [details].
Site and target enrollment: [details]. IRB: [name]. Expected Study period: [dates].
Sponsor responsible party for ClinicalTrials.gov: [name].
Sponsor monitor/safety/notice contacts: [details]. Institution regulatory/privacy/notice contacts: [details].
Insurance limits: Sponsor [amount/type]; Institution [amount/type].

SCHEDULE 2 — BUDGET
Start-up: [amount]. Per completed visit/procedure: [table]. Pharmacy: [amount]. Close-out: [amount]. Invoice schedule and payee: [details].

SIGNED for Sponsor: ____________________ Name/title: [name and title] Date: [date]

SIGNED for Institution: ____________________ Name/title: [name and title] Date: [date]

Investigator acknowledgment: I accept the Investigator duties assigned above. ____________________ Date: [date]


---
License: Licensed under CC BY 4.0. Attribution is required when you publish or redistribute this Template or an adapted version to the public. Attribution is not required merely because you use or adapt the Template for your own business or legal purposes, including preparing, negotiating, signing, or exchanging an agreement with a counterparty. License details.
License details: https://contract-templates.getfebruary.ai/license/